Clinical Scorecard: FDA approves first therapy for symptomatic dermographism
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: FDA approves first therapy for symptomatic dermographism
Key Mechanisms
Mechanisms or clinical associations described in the source article.
Target Population
Patients or participants described in the source article.
Care Setting
US treatment context for adults with symptomatic dermographism whose symptoms remain inadequately controlled with H1 antihistamines.
Key Highlights
The FDA approved remibrutinib (Rhapsido) as the first FDA-approved treatment for symptomatic dermographism.
Approval was supported by the symptomatic dermographism cohort of the phase 3 RemIND trial, which enrolled patients still symptomatic while taking second-generation H1 antihistamines.
At week 12, complete hive response occurred in 29.3% of patients receiving remibrutinib and 14.0% receiving placebo.
Responses were reported as early as week 2.
Routine laboratory monitoring is not required; common adverse events through week 24 included nasopharyngitis, bleeding, headache, nausea, and abdominal pain.
Guideline-Based Recommendations
Diagnosis
Management
Remibrutinib is FDA-approved for adults with symptomatic dermographism whose symptoms remain inadequately controlled with H1 antihistamines.
Monitoring & Follow-up
Routine laboratory monitoring is not required.
Risks
Through week 24, adverse events occurring in at least 3% of patients included nasopharyngitis, bleeding, headache, nausea, and abdominal pain.
The safety profile in symptomatic dermographism was reported as consistent with the profile in chronic spontaneous urticaria.
Patient & Prescribing Data
Adults with symptomatic dermographism inadequately controlled with H1 antihistamines; the RemIND cohort included patients symptomatic while taking second-generation H1 antihistamines.
In the phase 3 RemIND cohort, complete hive response at week 12 was 29.3% with remibrutinib versus 14.0% with placebo; responses were reported as early as week 2.
